ERBB2 and neoplasm: Among the 59 patients with available data on the primary tumor phenotype, 10 (17%) had a non-triple negative primary breast cancer: ER-positive, N = 8/59 (14%), PR-positive, N = 4/59 (7%), HER2-positive, N = 2/59 (3%).